Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer Immunotherapies.

Neal LR, Bailey SR, Wyatt MM, Bowers JS, Majchrzak K, Nelson MH, Haupt C, Paulos CM, Varela JC.

J Immunol Res Ther. 2017;2(1):68-79. Epub 2017 Jun 26.

2.

The Maintenance of Telomere Length in CD28+ T Cells During T Lymphocyte Stimulation.

Huang EE, Tedone E, O'Hara R, Cornelius C, Lai TP, Ludlow A, Wright WE, Shay JW.

Sci Rep. 2017 Jul 28;7(1):6785. doi: 10.1038/s41598-017-05174-7.

3.

Harnessing adaptive natural killer cells in cancer immunotherapy.

Liu LL, Pfefferle A, Yi Sheng VO, Björklund AT, Béziat V, Goodridge JP, Malmberg KJ.

Mol Oncol. 2015 Dec;9(10):1904-17. doi: 10.1016/j.molonc.2015.10.001. Epub 2015 Oct 20. Review.

4.

T cell engineering as therapy for cancer and HIV: our synthetic future.

June CH, Levine BL.

Philos Trans R Soc Lond B Biol Sci. 2015 Oct 19;370(1680):20140374. doi: 10.1098/rstb.2014.0374. Review.

5.

Advances in T-cell therapy for ALL.

Grupp SA.

Best Pract Res Clin Haematol. 2014 Sep-Dec;27(3-4):222-8. doi: 10.1016/j.beha.2014.10.014. Epub 2014 Oct 27. Review.

6.

An antiapoptotic role for telomerase RNA in human immune cells independent of telomere integrity or telomerase enzymatic activity.

Gazzaniga FS, Blackburn EH.

Blood. 2014 Dec 11;124(25):3675-84. doi: 10.1182/blood-2014-06-582254. Epub 2014 Oct 15.

7.

Telomere length in peripheral blood leukocytes is associated with risk of colorectal cancer in Chinese population.

Qin Q, Sun J, Yin J, Liu L, Chen J, Zhang Y, Li T, Shi Y, Wei S, Nie S.

PLoS One. 2014 Feb 3;9(2):e88135. doi: 10.1371/journal.pone.0088135. eCollection 2014.

8.

Engineering T cells for cancer: our synthetic future.

Vonderheide RH, June CH.

Immunol Rev. 2014 Jan;257(1):7-13. doi: 10.1111/imr.12143. No abstract available.

9.

Quantifying T lymphocyte turnover.

De Boer RJ, Perelson AS.

J Theor Biol. 2013 Jun 21;327:45-87. doi: 10.1016/j.jtbi.2012.12.025. Epub 2013 Jan 9.

10.

Homeostasis of lymphocytes and monocytes in frequent blood donors.

Ratts RB, Weng NP.

Front Immunol. 2012 Aug 22;3:271. doi: 10.3389/fimmu.2012.00271. eCollection 2012.

11.

Collapse of telomere homeostasis in hematopoietic cells caused by heterozygous mutations in telomerase genes.

Aubert G, Baerlocher GM, Vulto I, Poon SS, Lansdorp PM.

PLoS Genet. 2012;8(5):e1002696. doi: 10.1371/journal.pgen.1002696. Epub 2012 May 17.

12.

Immortalization of human and rhesus macaque primary antigen-specific T cells by retrovirally transduced telomerase reverse transcriptase.

Barsov EV.

Curr Protoc Immunol. 2011 Nov;Chapter 7:Unit 7.21B. doi: 10.1002/0471142735.im0721bs95.

13.

Maintaining the end: roles of telomere proteins in end-protection, telomere replication and length regulation.

Stewart JA, Chaiken MF, Wang F, Price CM.

Mutat Res. 2012 Feb 1;730(1-2):12-9. doi: 10.1016/j.mrfmmm.2011.08.011. Epub 2011 Sep 17. Review.

14.

A challenge for the future: aging and HIV infection.

Rickabaugh TM, Jamieson BD.

Immunol Res. 2010 Dec;48(1-3):59-71. doi: 10.1007/s12026-010-8167-9. Review.

15.

Induction/engineering, detection, selection, and expansion of clinical-grade human antigen-specific CD8 cytotoxic T cell clones for adoptive immunotherapy.

Jeras M, Bricl I, Zorec R, Svajger U.

J Biomed Biotechnol. 2010;2010:705215. doi: 10.1155/2010/705215. Epub 2010 Mar 10. Review.

16.

CD28(-) T cells: their role in the age-associated decline of immune function.

Weng NP, Akbar AN, Goronzy J.

Trends Immunol. 2009 Jul;30(7):306-12. doi: 10.1016/j.it.2009.03.013. Epub 2009 Jun 18. Review.

17.

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.

Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, Samanta M, Lakhal M, Gloss B, Danet-Desnoyers G, Campana D, Riley JL, Grupp SA, June CH.

Mol Ther. 2009 Aug;17(8):1453-64. doi: 10.1038/mt.2009.83. Epub 2009 Apr 21. Erratum in: Mol Ther. 2015 Jul;23(7):1278.

18.

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, Varela-Rohena A, Haines KM, Heitjan DF, Albelda SM, Carroll RG, Riley JL, Pastan I, June CH.

Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3360-5. doi: 10.1073/pnas.0813101106. Epub 2009 Feb 11.

19.

Telomerase-based pharmacologic enhancement of antiviral function of human CD8+ T lymphocytes.

Fauce SR, Jamieson BD, Chin AC, Mitsuyasu RT, Parish ST, Ng HL, Kitchen CM, Yang OO, Harley CB, Effros RB.

J Immunol. 2008 Nov 15;181(10):7400-6.

20.

Adoptive immunotherapy: good habits instilled at youth have long-term benefits.

Paulos CM, Suhoski MM, Plesa G, Jiang T, Basu S, Golovina TN, Jiang S, Aqui NA, Powell DJ Jr, Levine BL, Carroll RG, Riley JL, June CH.

Immunol Res. 2008;42(1-3):182-96. doi: 10.1007/s12026-008-8070-9. Review.

Supplemental Content

Support Center